Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (3) ·
Acetaminophen (paracetamol, APAP) (1) ·
Adalimumab (1) ·
Aspirin (acetylsalicylic acid; ASA) (1) ·
Azelastine (1) ·
Bimatoprost (1) ·
Bisacodyl (1) ·
Brimonidine (1) ·
Ciprofloxacin (1) ·
Diazepam (1) ·
Docusate (sodium or calcium) (1) ·
Dorzolamide (1) ·
Evolocumab (1) ·
Hydrocortisone (cortisol) (1) ·
Indomethacin (1) ·
Insulin aspart (1) ·
Insulin detemir (1) ·
Insulin lispro (1) ·
Ketotifen (1) ·
Latanoprost (1) ·
Levofloxacin (1) ·
Mesalamine (5-aminosalicylic acid, 5-ASA) (1) ·
Methotrexate (1) ·
Morphine (sulfate) (1) ·
Moxifloxacin (1) ·
Nitroglycerin (glyceryl trinitrate, GTN) (1) ·
Olopatadine (1) ·
Promethazine (hydrochloride) (1) ·
Sumatriptan (succinate) (1)
brand:
Aimovig (1) ·
Ajovy (1) ·
Alphagan P (ophthalmic glaucoma), Mirvaso (topical rosacea) (1) ·
Asacol HD, Pentasa, Lialda, Apriso, Delzicol, Rowasa (rectal), Canasa (suppository) (1) ·
Astelin, Astepro (intranasal); Optivar (ophthalmic); with fluticasone as Dymista (1) ·
Avelox (oral/IV brand discontinued US); Vigamox, Moxeza (ophthalmic) (1) ·
Bayer, Ecotrin, Bufferin, St. Joseph (low-dose 81 mg), Excedrin (with acetaminophen and caffeine) (1) ·
Cipro, Cipro XR, Ciloxan (ophthalmic) (1) ·
Colace (sodium), Surfak (calcium); many generics OTC (1) ·
Cortef (oral), Solu-Cortef (IV), many topical brands (Cortizone, OTC); Plenadren, Alkindi (modified-release for adrenal insufficiency) (1) ·
Dulcolax, Correctol, Bisac-Evac (1) ·
Emgality (1) ·
Humalog, Admelog, Lyumjev (1) ·
Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1) ·
Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) (1) ·
Indocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon (1) ·
Levaquin (US brand discontinued); generic and ophthalmic Quixin/Iquix (1) ·
Levemir, Levemir FlexTouch (US discontinuation announced 2024) (1) ·
Lumigan (glaucoma), Latisse (eyelash growth) (1) ·
MS Contin (ER), Kadian (ER), Avinza (ER), Roxanol (IR oral solution), Duramorph (epidural / IT), Astramorph (IV), Infumorph (intrathecal pump), MorphaBond (IR abuse-deterrent) (1) ·
Nitrostat, Nitrolingual, NitroMist, Nitro-Bid, Nitro-Dur, Minitran, Rectiv (1) ·
NovoLog, Fiasp (ultra-rapid), Trurapi (1) ·
Patanol, Pataday (ophthalmic, now OTC), Patanase (intranasal) (1) ·
Phenergan, Promethegan (suppositories) (1) ·
Repatha (1) ·
Trexall, Otrexup, Rasuvo, Xatmep, Rheumatrex (discontinued) (1) ·
Trusopt; with timolol as Cosopt (1) ·
Tylenol, Panadol (international), Ofirmev (IV); huge OTC presence (1) ·
Valium (oral, IV/IM, rectal), Diastat (rectal gel for breakthrough seizures), Valtoco (nasal spray for breakthrough seizures), Libervant (buccal film) (1) ·
Xalatan, Xelpros (1) ·
Zaditor, Alaway (ophthalmic, OTC); Zaditen (systemic, outside US) (1)
classes:
[[:Category:Analgesics|Analgesic]] (4) ·
[[:Category:Glaucoma_medications|Glaucoma medication]] (4) ·
[[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]] (4) ·
[[:Category:Antibacterials|Antibacterial]] (3) ·
[[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]] (3) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]] (3) ·
[[:Category:Insulins|Insulin]] (3) ·
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] (3) ·
Anti-CGRP ligand monoclonal antibody (2) ·
[[:Category:Antipyretics|Antipyretic]] (2) ·
[[:Category:Biologics|Biologic]] (2) ·
[[:Category:DMARDs|DMARD]] (2) ·
[[:Category:Immunosuppressants|Immunosuppressant]] (2) ·
[[:Category:Mealtime_insulins|Mealtime (bolus) insulin]] (2) ·
[[:Category:Ophthalmic_antihistamines|Ophthalmic antihistamine]] (2) ·
[[:Category:Prostaglandin_analogs|Prostaglandin F2α analog]] (2) ·
[[:Category:Rapid-acting_insulins|Rapid-acting insulin analog]] (2)
mechanism:
None (21) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
'"`UNIQ--vote-00000584-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio. Ultra-rapid formulations (Lyumjev) add treprostinil and citrate to accelerate absorption further'"`UNIQ--ref-00000585-QINU`"'. (1) ·
'"`UNIQ--vote-00000D7A-QINU`"' Substantial QT-interval prolongation — the most QT-prolonging fluoroquinolone — limits use in patients on other QT-prolonging agents or with electrolyte abnormalities'"`UNIQ--ref-00000D7B-QINU`"'. (1) ·
'"`UNIQ--vote-00001067-QINU`"' Chronic use is associated with cathartic colon (colonic dilation, loss of haustration), hypokalemia, and laxative dependence; reserved for short-term use or bowel prep with breaks between courses'"`UNIQ--ref-00001068-QINU`"'. (1) ·
'"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1) ·
'"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1) ·
'"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1) ·
'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'. (1)
uses:
None (1) ·
Preventive treatment of migraine in adults (episodic and chronic) (2) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (2) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"' (1) ·
'"`UNIQ--vote-00000415-QINU`"', '"`UNIQ--vote-00000416-QINU`"' (1) ·
'"`UNIQ--vote-00000586-QINU`"', '"`UNIQ--vote-00000587-QINU`"', '"`UNIQ--vote-00000588-QINU`"' (1) ·
'"`UNIQ--vote-000005EF-QINU`"', '"`UNIQ--vote-000005F0-QINU`"', '"`UNIQ--vote-000005F1-QINU`"' (1) ·
'"`UNIQ--vote-000006A2-QINU`"', '"`UNIQ--vote-000006A3-QINU`"', '"`UNIQ--vote-000006A4-QINU`"' (1) ·
'"`UNIQ--vote-000007C1-QINU`"', '"`UNIQ--vote-000007C2-QINU`"', '"`UNIQ--vote-000007C3-QINU`"', '"`UNIQ--vote-000007C4-QINU`"', '"`UNIQ--vote-000007C5-QINU`"', '"`UNIQ--vote-000007C6-QINU`"', '"`UNIQ--vote-000007C7-QINU`"' (1) ·
'"`UNIQ--vote-00000932-QINU`"', '"`UNIQ--vote-00000933-QINU`"', '"`UNIQ--vote-00000934-QINU`"', '"`UNIQ--vote-00000935-QINU`"', '"`UNIQ--vote-00000936-QINU`"', '"`UNIQ--vote-00000937-QINU`"' (1) ·
'"`UNIQ--vote-00000ACD-QINU`"', '"`UNIQ--vote-00000ACE-QINU`"', '"`UNIQ--vote-00000ACF-QINU`"', '"`UNIQ--vote-00000AD0-QINU`"' (1) ·
'"`UNIQ--vote-00000B08-QINU`"', '"`UNIQ--vote-00000B09-QINU`"' (1) ·
'"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1) ·
'"`UNIQ--vote-00000C0A-QINU`"', '"`UNIQ--vote-00000C0B-QINU`"', '"`UNIQ--vote-00000C0C-QINU`"', '"`UNIQ--vote-00000C0D-QINU`"', '"`UNIQ--vote-00000C0E-QINU`"' (1) ·
'"`UNIQ--vote-00000CEF-QINU`"', '"`UNIQ--vote-00000CF0-QINU`"', '"`UNIQ--vote-00000CF1-QINU`"', '"`UNIQ--vote-00000CF2-QINU`"', '"`UNIQ--vote-00000CF3-QINU`"', '"`UNIQ--vote-00000CF4-QINU`"' (1) ·
'"`UNIQ--vote-00000D7C-QINU`"', '"`UNIQ--vote-00000D7D-QINU`"', '"`UNIQ--vote-00000D7E-QINU`"', '"`UNIQ--vote-00000D7F-QINU`"', '"`UNIQ--vote-00000D80-QINU`"', '"`UNIQ--vote-00000D81-QINU`"' (1) ·
'"`UNIQ--vote-00000D9E-QINU`"', '"`UNIQ--vote-00000D9F-QINU`"', '"`UNIQ--vote-00000DA0-QINU`"' (1) ·
'"`UNIQ--vote-00001069-QINU`"', '"`UNIQ--vote-0000106A-QINU`"' (1) ·
'"`UNIQ--vote-000010CE-QINU`"', '"`UNIQ--vote-000010CF-QINU`"', '"`UNIQ--vote-000010D0-QINU`"' (1) ·
'"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"' (1) ·
'"`UNIQ--vote-00001286-QINU`"' (1) ·
'"`UNIQ--vote-00001341-QINU`"', '"`UNIQ--vote-00001342-QINU`"' (1) ·
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1) ·
'"`UNIQ--vote-000013B3-QINU`"', '"`UNIQ--vote-000013B4-QINU`"', '"`UNIQ--vote-000013B5-QINU`"' (1) ·
'"`UNIQ--vote-0000147C-QINU`"', '"`UNIQ--vote-0000147D-QINU`"', '"`UNIQ--vote-0000147E-QINU`"' (1)
starting dose:
1 drop in affected eye(s) TID (monotherapy); BID with timolol (Cosopt) (1) ·
1 drop in the affected eye(s) once daily in the evening (1) ·
1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime (1) ·
100-200 mg PO once or twice daily; pediatric weight-based (1) ·
140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume) (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours (1) ·
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) ·
400 mg PO/IV once daily (1) ·
5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses (1) ·
500-750 mg PO BID; 400 mg IV q8-12h (1) ·
500-750 mg PO/IV once daily (1) ·
70 mg SC monthly; may increase to 140 mg monthly (1) ·
Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1) ·
Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) ·
Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' (1) ·
Antiplatelet: 81 mg PO once daily. Acute MI/stroke: 162-325 mg chewed. Analgesic: 325-650 mg PO every 4-6 hours as needed (1) ·
Anxiety: 2-10 mg PO 2-4 times daily. Alcohol withdrawal: 10-20 mg PO/IV every 4-6 hours, symptom-triggered. Status epilepticus: 5-10 mg IV. Breakthrough seizures: Diastat rectal 0.2-0.5 mg/kg or Valtoco intranasal 5-20 mg (1) ·
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID (1) ·
IR oral: 15-30 mg every 4 hours as needed. ER opioid-naive: 15-30 mg every 12 hours. IV/IM/SC: 2-10 mg every 3-4 hours. Epidural / intrathecal: see surgical or palliative-care protocols (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily (1) ·
Ophthalmic 1 drop in each eye every 8-12 hours (1) ·
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1) ·
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1) ·
Physiologic replacement 15-25 mg/d divided (e.g., 10 mg AM, 5 mg noon, 5 mg afternoon); stress dose 50-100 mg IV q6-8h; adrenal crisis 100 mg IV then 50-100 mg q6h; topical 0.5-2.5% applied 2-4×/d (1) ·
Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific (1) ·
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose (1) ·
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose. Typical total daily dose 0.5-1 U/kg/d split between basal and prandial coverage in T1DM (1) ·
SL 0.3-0.6 mg every 5 minutes up to 3 doses for acute angina (call EMS if not resolved after the third); IV infusion 5-10 mcg/min titrated; transdermal patch 0.2-0.4 mg/hr for 12-14 hours daily (nitrate-free interval prevents tolerance) (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)
preparations:
0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle (1) ·
0.01%, 0.03% ophthalmic solution (1) ·
0.025%, 0.035% ophthalmic solutions (1) ·
0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1) ·
0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) (1) ·
0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza) (1) ·
100 U/mL (Humalog, Admelog, Lyumjev) vials, pens, cartridges; 200 U/mL Humalog KwikPen (1) ·
100 U/mL (NovoLog, Fiasp) vials, pens, cartridges (1) ·
100 U/mL FlexTouch pen, vial (1) ·
120 mg/mL prefilled syringe or autoinjector (1) ·
140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor (1) ·
2% ophthalmic solution (Trusopt); 2%/0.5% fixed combination with timolol (Cosopt, Cosopt PF) (1) ·
2.5 mg tablets; 10-50 mg/mL injection; pre-filled subcutaneous autoinjectors (Otrexup, Rasuvo); 2.5 mg/mL oral solution (Xatmep) (1) ·
225 mg/1.5 mL prefilled syringe or autoinjector (1) ·
250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic (1) ·
250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions (1) ·
325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines (1) ·
40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1) ·
400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution (1) ·
5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx (1) ·
5, 10, 20 mg oral tablets; 100, 250, 500, 1000 mg IV (Solu-Cortef); 0.5%, 1%, 2.5% topical creams/ointments; rectal foam and enemas (1) ·
50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC (1) ·
70 mg/mL or 140 mg/mL prefilled autoinjector (1) ·
Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) ·
IR tablets 15, 30 mg; oral solution 10 mg/5 mL, 20 mg/mL, 100 mg/5 mL (concentrated); suppositories; ER tablets and capsules in multiple strengths; injectable 0.5-50 mg/mL (1) ·
Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository (1) ·
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1) ·
SL 0.3, 0.4, 0.6 mg tablets; lingual spray 0.4 mg/spray; ER 2.5-9 mg capsules; transdermal patch 0.1-0.8 mg/hr; 2% ointment; 0.4% rectal ointment; 5 mg/mL IV (1) ·
Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL (1) ·
Tablets 2, 5, 10 mg; oral solution 1, 5 mg/mL; injection 5 mg/mL; Diastat rectal gel 2.5, 5, 10, 20 mg; Valtoco nasal spray 5, 7.5, 10 mg/dose; Libervant buccal film (1) ·
Tablets 81 (low-dose), 325, 500, 650 mg; chewable 81 mg; enteric-coated tablets; effervescent tablets; suppositories (1)
fda max:
1 drop per eye q8-12h (1) ·
1 drop/eye/day (more frequent dosing reduces efficacy) (1) ·
100 mg/day (adult) (1) ·
140 mg/month (1) ·
2 sprays/nostril BID (1) ·
200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra) (1) ·
200 mg/day (typical adult oral) (1) ·
240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) ·
30 mg/d for short-term use (1) ·
4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use (1) ·
40 mg every week (selected indications); otherwise 40 mg every other week (1) ·
40 mg/day (oral, anxiety) (1) ·
400 mg/d (1) ·
4000 mg/day (analgesic) (1) ·
420 mg/month (1) ·
675 mg/quarter (1) ·
750 mg/d (1) ·
Formulation-specific; ~4.8 g/d typical maximum oral (1) ·
Indication-specific (1) ·
Indication-specific; titrated to effect (1) ·
No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals (1) ·
Once daily (Pataday 0.7%); BID (other ophthalmic) (1) ·
One drop per eye per day (1) ·
Rheumatologic ~25 mg/week; oncology indication-specific (1) ·
TID per eye (2) ·
Titrated to glucose (1) ·
Titrated to glucose; no fixed maximum (2) ·
~1500 mg/d (oral); 1200 mg/d (IV) (1) ·
~500 mg/d typical (1)
routes: (Click arrow to add another value)
onset:
1-2 hours (1) ·
1-3 days (1) ·
10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) (1) ·
15 minutes (1) ·
15-60 minutes (oral); 1-5 minutes (IV); 4-10 minutes (rectal or intranasal) (1) ·
20 minutes (oral); 5 minutes (IV) (1) ·
30-60 minutes (oral); rapid relief in acute gout (1) ·
5-10 minutes (IV); 30 minutes (oral IR); slower for ER and rectal (1) ·
Antiplatelet effect within 30-60 minutes; analgesic effect 30-60 minutes (1) ·
Hours (4) ·
IOP lowering at 1 hour; max at 2-3 hours (1) ·
IOP lowering at 2 hours; max at 4 hours (1) ·
IOP lowering at 3-4 hours; maximum at 8-12 hours (1) ·
IOP lowering at 4 hours, maximum at 8-12 hours; eyelash effect after 2 months (1) ·
LDL reduction ~50-60% from baseline at 1-2 weeks (1) ·
Onset of preventive effect over weeks; some patients respond after first dose (1) ·
Over weeks (2) ·
PO 6-12 hours; PR 15-60 minutes (1) ·
PO: 30-60 minutes; IV: minutes (1) ·
Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks (1) ·
SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average) (1) ·
SC: 5-15 minutes; ultra-rapid Lyumjev faster (1) ·
SL/spray: 1-3 minutes; IV: minutes; patch: 30-60 minutes (1) ·
Symptom relief within 30-60 minutes (1) ·
Symptomatic effect within weeks; full response by 12-24 weeks (1) ·
Symptomatic improvement 2-4 weeks (1) ·
Within minutes (1)
duration:
'''Antiplatelet effect lasts the platelet's lifetime (~7-10 days)''' due to irreversible COX-1 acetylation; analgesic 4-6 hours (1) ·
12 hours (1) ·
2 weeks per dose (1) ·
2-4 hours; headache recurrence rate ~20-30% within 24 hours (1) ·
2-4 weeks per dose (1) ·
24 hours (4) ·
24 hours (0.7% formulation); 8-12 hours (lower-strength) (1) ·
24 hours (most ER formulations) (1) ·
3-5 hours (2) ·
3-5 hours (IR); 8-24 hours (ER); 12-24 hours (epidural / intrathecal) (1) ·
4-6 hours (2) ·
4-6 hours (IR); 24 hours (ER) (1) ·
6-24 hours (parent); much longer when accounting for the long-lived active metabolites (1) ·
8-12 hours (3) ·
8-12 hours (TID dosing needed) (1) ·
Biologic ~8-12 hours (short-acting) (1) ·
Hours (2) ·
Monthly dosing (2) ·
Monthly or quarterly dosing (1) ·
Once-weekly dosing in rheumatology (1) ·
SL: 30 minutes; patch: 12-14 hours; IV continuous (1) ·
~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1)
halflife:
1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion'"`UNIQ--ref-000006A5-QINU`"' (1) ·
1-3 minutes (very short)'"`UNIQ--ref-00000C0F-QINU`"' (1) ·
12-15 hours'"`UNIQ--ref-00000022-QINU`"' (1) ·
2 hours'"`UNIQ--ref-00000015-QINU`"' (1) ·
3-10 hours (low dose); 8-15 hours (high dose); much longer in third-space accumulation (pleural effusion, ascites)'"`UNIQ--ref-000007C8-QINU`"' (1) ·
4 hours'"`UNIQ--ref-00000938-QINU`"' (1) ·
4-5 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
Aspirin 15-30 minutes; salicylate metabolite 2-3 hours (concentration-dependent, saturable at high doses)'"`UNIQ--ref-00000027-QINU`"' (1) ·
Diazepam 20-50 hours; '''N-desmethyldiazepam (nordazepam) 30-200 hours''' is the major active metabolite and accumulates substantially with chronic dosing'"`UNIQ--ref-00000026-QINU`"' (1) ·
Morphine 2-4 hours; morphine-6-glucuronide active metabolite 2-4 hours (longer with renal impairment)'"`UNIQ--ref-00000020-QINU`"' (1) ·
Not meaningfully described (1) ·
Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) ·
Plasma ~1-2 hours; biologic ~8-12 hours'"`UNIQ--ref-00000AD1-QINU`"' (1) ·
Variable; effect dependent on local intestinal action rather than systemic kinetics'"`UNIQ--ref-0000106B-QINU`"' (1) ·
~1 hour SC'"`UNIQ--ref-00000589-QINU`"' (1) ·
~11-17 days'"`UNIQ--ref-0000147F-QINU`"' (1) ·
~12 hours'"`UNIQ--ref-00000D82-QINU`"' (1) ·
~14 days'"`UNIQ--ref-00001103-QINU`"' (1) ·
~17 minutes (free acid, the active form, in aqueous humor)'"`UNIQ--ref-00000417-QINU`"' (1) ·
~22 hours; longer 54 hours (desmethylazelastine, active metabolite)'"`UNIQ--ref-000013B6-QINU`"' (1) ·
~27 days (1) ·
~28 days (1) ·
~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"' (1) ·
~3 hours'"`UNIQ--ref-000010D1-QINU`"' (1) ·
~31 days (1) ·
~4 months in erythrocytes (carbonic anhydrase binding in red cells; not relevant to topical IOP duration)'"`UNIQ--ref-00000B0A-QINU`"' (1) ·
~45 minutes (free acid in aqueous humor)'"`UNIQ--ref-00000DA1-QINU`"' (1) ·
~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' (1) ·
~6-8 hours'"`UNIQ--ref-00000CF5-QINU`"' (1) ·
~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1) ·
~80 minutes SC'"`UNIQ--ref-000005F2-QINU`"' (1)
bioavailability:
60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"' (1) ·
Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' (1) ·
Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"' (1) ·
Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"' (1) ·
Local action; minimal systemic effect (1) ·
Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"' (1) ·
Not formally established (1) ·
Not formally established (high SC) (1) ·
Topical with measurable systemic absorption (small CA inhibition observed clinically with chronic use)'"`UNIQ--ref-00000B0B-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) ·
Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"' (1) ·
Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"' (1) ·
Topical; minimal systemic absorption'"`UNIQ--ref-00000DA2-QINU`"' (1) ·
~100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~100% from subcutaneous depot (2) ·
~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' (1) ·
~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"' (1) ·
~25-40% (oral; extensive first-pass)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~50% (oral; reduced by buffering and enteric coating but onset clinically similar)'"`UNIQ--ref-00000028-QINU`"' (1) ·
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1) ·
~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1) ·
~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' (1) ·
~72% from SC depot'"`UNIQ--ref-00001480-QINU`"' (1) ·
~82% SC (1) ·
~85-98% (oral)'"`UNIQ--ref-000006A6-QINU`"' (1) ·
~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"' (1) ·
~93% (oral); ~90% (rectal)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~96% (oral)'"`UNIQ--ref-00000AD2-QINU`"' (1) ·
~99% (oral; matched 1:1 IV-to-PO conversion)'"`UNIQ--ref-00000CF6-QINU`"' (1)
pregnancy:
None (1) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern); use only when benefit clearly outweighs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Contraindicated in pregnancy''' (Category X); abortifacient and teratogenic. Discontinuation 3-6 months before conception is standard.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) ·
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable for short-term use.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; lispro is widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited data; avoid (3) ·
Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh against alternatives, though systemic exposure is low.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Long the preferred analgesic-antipyretic in pregnancy; recent observational studies have raised speculative neurodevelopmental signals that remain under investigation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Low-dose (81 mg) safe and indicated for preeclampsia prophylaxis after 12 weeks in high-risk patients per USPSTF; high-dose aspirin avoid third trimester due to premature ductus arteriosus closure and bleeding risk (1) ·
Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data'"`UNIQ--ref-00000024-QINU`"' (1) ·
One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Some signal for cleft palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Use when benefits outweigh; widely used at physiologic doses for adrenal insufficiency.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used in obstetric emergencies (uterine relaxation, severe hypertension) when needed; otherwise limited routine use.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (3) ·
OTC (Astepro 0.15%) and [[USLegal:Prescription only|Rx-only]] (other intranasal, ophthalmic, Dymista) in US (1) ·
OTC (low-dose topicals) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US (1) ·
OTC and [[USLegal:Prescription only|Rx-only]] (IV, combination products) in US (1) ·
OTC in US (3) ·
Rx (3) ·
[[USLegal:Over-the-counter|OTC]] in US at all standard strengths (1) ·
[[USLegal:Prescription only|Rx-only]] in US (12) ·
[[USLegal:Prescription only|Rx-only]] in US (some OTC formulations exist) (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-00000D84-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin: tendinitis/tendon rupture (especially elderly, corticosteroid co-use), peripheral neuropathy, CNS effects, worsening of myasthenia gravis'"`UNIQ--ref-00000CF7-QINU`"' (1) ·
[[USLegal:Schedule II|Schedule II controlled substance]] in US; WHO essential medicine'"`UNIQ--ref-00000022-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000028-QINU`"' (1)
Showing below up to 32 results in range #1 to #32.